ELEKTA CHOSEN TO DELIVER SOPHISTICATED BRAIN MAPPING TECHNOLOGY TO THE NEBRASKA MEDICAL CENTER


ELEKTA CHOSEN TO DELIVER SOPHISTICATED BRAIN MAPPING TECHNOLOGY TO THE NEBRASKA
MEDICAL CENTER

Press Release 
Stockholm, Sweden, February 11, 2008

Elekta Neuromag®, the world-leading equipment for non-invasive measurement of
brain activity using Magnetoencephalography (MEG) technology, has been ordered
by The Nebraska Medical Center in Omaha, USA.


With a reputation for excellence, innovation and extraordinary patient care, The
Nebraska Medical Center has earned J.D. Power and Associates' Hospital of
Distinction award for three consecutive years.
As the teaching hospital for the University of Nebraska Medical Center, this 689
licensed bed academic medical center has an international reputation for
providing solid organ and bone marrow transplantation services and is well known
nationally and regionally for its oncology, neurology and cardiology programs.
With a history dating back to 1869, dedication to compassionate, quality patient
care is the cornerstone of The Nebraska Medical Center. The not-for-profit
hospital is known for excellence and innovation in medicine.
The Nebraska Medical Center is Nebraska's largest health care facility - with
more than 4,900 employees and more than 1,000 physicians on staff. Its
physicians practice in all major specialties and sub-specialties attracting
patients from across the region and from around the world.

The Nebraska Medical Center will receive its new Elekta Neuromag MEG system in
the spring/summer of 2008. With the MEG system from Elekta installed,
neurosurgeons, neurologists and those in related fields will be able to
non-invasively record human brain activity in real time, better and more
accurately than ever before.

MEG technology is regarded as the most efficient method for tracking brain
activity at millisecond resolution. Compared to EEG technology, MEG has uniquely
accurate localization capabilities. Other technologies, for example Computed
Tomography (CT) and Magnetic Resonance Imaging (MRI), provide only anatomical or
metabolic information; whereas MEG is a direct measure of neuronal electric
activity. When complemented with MRI, MEG increases the ability to understand
brain activity and to improve treatment of functional disorders and, in
particularly, Epilepsy.

“We are extremely excited about our upcoming Magnetoencephalography system
installation,” said Dr. Sanjay Singh, Director of The Nebraska Epilepsy Center
at The Nebraska Medical Center and Associate Professor in the Department of
Neurological Sciences at the University of Nebraska Medical Center.

“We plan to use the MEG extensively as a vital part of our pre-surgical epilepsy
evaluation. The highly accurate localization capability is exactly what is
needed when dealing with complex intractable epilepsy cases.” Singh continued,
“The Nebraska Medical Center is home to a comprehensive epilepsy program that
serves Nebraska and the surrounding region. It provides new hope and
opportunities to people with epilepsy with a multi-phase monitoring and
treatment program using some of the most advanced diagnostic equipment
available. Adding MEG technology will enable our doctors to more accurately
pinpoint the site of a seizure and determine the type of epilepsy. The Elekta
Neuromag seems ideally suited to helping us to deal with the most difficult to
treat epilepsy patients, many of whom do not respond well to medications.
Particularly useful is the Elekta technology which will allow us to measure
patients that have an implanted vagal nerve stimulator.”

“We wish The Nebraska Medical Center every success with the treatment of their
patients and hope that the MEG system will provide valuable additional
information,” said Tomas Puusepp, President and CEO of Elekta. “We are pleased
that this technology can make a difference in the quality of patient care, even
in difficult cases.”

Elekta Neuromag®

The Elekta Neuromag 306-channel MEG sensor array has a higher density of
detectors than any other system on the market, leading to a more accurate
representation of brain activity. The industry's lowest signal-to-noise ratio
means that more useful information is acquired, thus yielding the highest
information per sample.

The unique design of the sensors combined with advanced software makes it
possible to gain data with unsurpassed detail, even from the deepest regions of
the brain. The system also has the highest available immunity to magnetic
interference, either patient-related or external. Elekta Neuromag also has also
the lowest operational costs. Elekta Neuromag is technically the most
sophisticated MEG/EEG device available on the market today.



********
For further information, please contact:

Clinical or scientific inquiries: 
Michael Enwall:
Director, MEG Marketing Europe & AFLAME
Tel: +46 8 587 25 448, e-mail: michael.enwall@elekta.com

or

Gordon Haid
Director of Sales, North America, Functional Mapping Business Unit
Tel: +1-604-395-5339, e-mail: gordon.haid@elekta.com

Investor Enquiries:
Peter Ejemyr, Group VP Corporate Communications.
Tel: +46 733 611 000 (mobile), e-mail: peter.ejemyr@elekta.com
About Elekta

Elekta is an international medical technology group, providing oncologists,
radiation therapists, neurosurgeons and many other medical specialists with
state of the art tools to fight serious disease.

Elekta provides advanced clinical solutions, comprehensive management and
information systems as well as services for improved cancer care and management
of brain disorders. 

Elekta's systems and solutions are used in over 4,500 hospitals around the
world. Clinical and information management solutions include, among others,
Leksell Gamma Knife® for non-invasive treatment of brain disorders, Elekta
Axesse™ and Elekta Synergy® for stereotactic and image guided radiation therapy
and radiosurgery as well as the MOSAIQ™ suite of software for image-enabled EMR
and efficient management of clinical and patient data.

With over 2,000 employees globally, the corporate headquarter is located in
Stockholm, Sweden and the company is listed on the Nordic Exchange under the
ticker EKTAb. More information about Elekta can be found at www.elekta.com.

Attachments

02112699.pdf